1..二季度比预期要好的两位数增长
MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH
2.分子诊断，如在冠状病毒类检测业务加速
The Life Science segment achieved record sales in the quarter, produced by unprecedented demand for its molecular products, specifically those designed for the detection of RNA viruses such as SARS-CoV-2. Demand continues to accelerate and while the longevity of the COVID-19 pandemic is unclear, increased revenue year-over-year in the third quarter of fiscal 2020 is also expected.
3.胃肠幽门螺杆菌相关检测新产品获fda批准
As announced on March 16th, the Diagnostics business also received FDA approval for the Curian® analyzer and the Curian® HpSA® assay, which are expected to begin shipping in the third quarter of fiscal 2020.
4.抗新冠战役，公司35+诊断试剂产品继续供应
We continue to be proud of the contribution that Meridian is making in the global fight against the COVID-19 pandemic. Our reagents are now included in 35+ diagnostic tests across China, Australia, Europe and the United States, and the Life Science team is working tirelessly to keep up with the demand,”
5.并购exalenz预期上半年完成
Pending Acquisition of Exalenz Bioscience
Exalenz Bioscience shareholders approved the proposed merger with Meridian on March 31, 2020. While the merger remains subject to the satisfaction of other customary closing conditions, the Company continues to expect to complete the acquisition before June 30, 2020.
6.总的来说，同行有受疫情影响较大的，公司则运营良好
In general, Meridian maintains a multi-month inventory of raw materials and other components, and our suppliers continue to meet our demand. Where there has been some disruption or delay in supply, we have qualified backup suppliers and are continuously monitoring our supply chains. Many of our clinical trial partners have suspended operations, which will likely result in delays for our products in the pipeline.
